Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Cariprazine (Vraylar) for schizophrenia and acute manic or mixed episodes in bipolar I disorder. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2016 Authors' conclusions Description of Technology: Cariprazine (Vraylar) is an orally administered atypical antipsychotic agent used to treat patients with acute exacerbation of schizophrenia or acute manic or mixed episodes associated with bipolar I disorder. Among antipsychotic drugs, the binding affinity profile of cariprazine is most similar to that of aripiprazole. Cariprazine acts as a partial agonist, having high affinity for the dopamine D3 and D2 receptors and moderate affinity for serotonin 5-HT1A receptors. Its moderate to low binding affinity for histamine H1 and 5-HT2C receptors may be associated with fewer endocrine and metabolic side effects and less sedation. Its 6- to 10-times higher affinity for the D3 receptor than the D2 receptor might improve cognitive deficits and mood and reduce side effects. Lower binding affinity at the 5-HT1A receptor may be responsible for improvement in the negative symptoms of schizophrenia.
Patient Population: Cariprazine is used to treat patients with acute exacerbation of schizophrenia or acute manic or mixed episodes associated with bipolar I disorder. Indexing Status Subject indexing assigned by CRD MeSH Bipolar Disorder; Humans; Piperazines; Schizophrenia Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32016000784 Date abstract record published 15/06/2016 |